PKD (Protein kinase D) is an evolutionarily conserved protein kinase family with structural, enzymological, and regulatory properties different from the PKC family members.A surprisingly wide range of stimuli, such as polypeptide growth factors and agonists of G-protein-coupled receptors, can trigger signaling through PKD. There are three members of the serine/threonine protein kinase PKD family: PKD1, PKD2, and PKD3. The family member that has been studied the most, PKD1, is becoming more and more involved in the control of a wide range of basic biological processes, such as signal transduction, angiogenesis, membrane trafficking, secretion, immune regulation, cardiac hypertrophy and contraction, and cancer. Due to its unique substrate specificity and dynamic shifts in both spatial and temporal localization, PKD mediates a wide range of biological functions, both normal and abnormal.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V0452 | CID-2011756 | 638156-11-3 | CID-2011756, discovered from an HTS-high throughput screening campaign, is a cell-permeable, ATP-competitive and specific inhibitor of PKD (protein kinase D) with potential anticancer activity. | |
V11937 | CRT 0066101 | 1883545-60-5 | CRT 0066101 is a novel, potent and selective inhibitor of protein kinase D (PKD) with IC50 values of 1, 2.5 and 2 nM for PKD1, 2, and 3 respectively. | |
V88534 | CRT0066101 | 956123-34-5 | CRT0066101 is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2 and PKD3, respectively. | |
V2279 | CRT5 | 1034297-58-9 | CRT5(also known as CRT-0066051) is a novel pyrazine benzamide that potent prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC50 s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). | |
V88535 | PKC/PKD-IN-1 | 1071135-06-2 | PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC50 of 0.6 nM for PKD1. |